The results of a phase III clinical trial with pelacarsen have revealed that the reduction of lipoprotein (a) does not decrease the risk of experiencing serious cardiovascular events, challenging the hypothesis about its protective role in heart disease. #LipoproteínaA #SaludCardiovascular #InvestigaciónMédica (translated)
















